These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22454423)

  • 41. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
    Lamba JK; Fridley BL; Ghosh TM; Yu Q; Mehta G; Gupta P
    Pharmacogenomics; 2014; 15(12):1565-74. PubMed ID: 25340731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
    Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
    J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single nucleotide polymorphisms in tobacco metabolism and DNA repair genes and prognosis in resected non-small-cell lung cancer.
    Campayo M; Viñolas N; Navarro A; Carcereny E; Casas F; Gel B; Diaz T; Gimferrer JM; Marrades RM; Ramirez J; Monzo M
    J Surg Res; 2011 May; 167(1):e5-12. PubMed ID: 21324488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.
    Du Y; Su T; Zhao L; Tan X; Chang W; Zhang H; Cao G
    PLoS One; 2014; 9(6):e99843. PubMed ID: 24933103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
    Li Y; Sun Z; Cunningham JM; Aubry MC; Wampfler JA; Croghan GA; Johnson C; Wu D; Aakre JA; Molina J; Wang L; Pankratz VS; Yang P
    Clin Cancer Res; 2011 Jun; 17(11):3830-40. PubMed ID: 21636554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
    Ogino S; Hazra A; Tranah GJ; Kirkner GJ; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Meyerhardt JA; Hunter DJ; Fuchs CS
    Carcinogenesis; 2007 Sep; 28(9):1985-90. PubMed ID: 17621591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survival.
    Yang S; Tang D; Zhao YC; Liu H; Luo S; Stinchcombe TE; Glass C; Su L; Shen S; Christiani DC; Wang Q; Wei Q
    Int J Cancer; 2020 Jul; 147(2):392-403. PubMed ID: 31618441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A systematic review and meta-analysis: Association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma.
    Chen L; Wang Y; Liu F; Xu L; Peng F; Zhao N; Fu B; Zhu Z; Shi Y; Liu J; Wu R; Wang C; Yao S; Li Y
    Sci Rep; 2018 Jan; 8(1):1439. PubMed ID: 29362385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic and Predictive Value of O
    Zhang J; Zhu Y; Wang Y; Fu Q; Xie H; Liu Z; Fu H; Cao Y; Xu J; Dai B
    Ann Surg Oncol; 2018 Jan; 25(1):342-348. PubMed ID: 29116491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A meta-analysis of Association between MGMT gene promoter methylation and non-small cell lung cancer].
    Fang N; Gu J; Wei H; You J; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):601-5. PubMed ID: 25130966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.
    Han ZG; Tao J; Yu TT; Shan L
    Med Sci Monit; 2017 Apr; 23():1999-2006. PubMed ID: 28442702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.
    Wu X; Ye Y; Rosell R; Amos CI; Stewart DJ; Hildebrandt MA; Roth JA; Minna JD; Gu J; Lin J; Buch SC; Nukui T; Ramirez Serrano JL; Taron M; Cassidy A; Lu C; Chang JY; Lippman SM; Hong WK; Spitz MR; Romkes M; Yang P
    J Natl Cancer Inst; 2011 May; 103(10):817-25. PubMed ID: 21483023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
    Bi N; Yang M; Zhang L; Chen X; Ji W; Ou G; Lin D; Wang L
    Clin Cancer Res; 2010 Apr; 16(8):2383-90. PubMed ID: 20332326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
    Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinicopathological factors predictive of postoperative seizures in patients with gliomas.
    Yang P; Liang T; Zhang C; Cai J; Zhang W; Chen B; Qiu X; Yao K; Li G; Wang H; Jiang C; You G; Jiang T
    Seizure; 2016 Feb; 35():93-9. PubMed ID: 26808114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
    Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
    BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
    McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
    Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer.
    Szczyrek M; Mlak R; Krawczyk P; Wojas-Krawczyk K; Powrózek T; Szudy-Szczyrek A; Zwolak A; Daniluk J; Milanowski J
    Pathol Oncol Res; 2017 Jul; 23(3):607-614. PubMed ID: 27988838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma.
    Melchers LJ; Clausen MJ; Mastik MF; Slagter-Menkema L; van der Wal JE; Wisman GB; Roodenburg JL; Schuuring E
    Epigenetics; 2015; 10(9):850-60. PubMed ID: 26213212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.